{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+2+in+Part+A&page=7", "query": { "intervention": "Cohort 2 in Part A", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 1309, "total_pages": 131, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+2+in+Part+A&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cohort+2+in+Part+A&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T21:02:46.035Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00960960", "title": "A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, and With Letrozole, in Participants With Locally Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pictilisib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2009-08", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-12-15", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 3, "location_summary": "Peoria, Illinois • Boston, Massachusetts • Nashville, Tennessee", "locations": [ { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00960960" }, { "nct_id": "NCT03462342", "title": "Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Serous Carcinoma" ], "interventions": [ { "name": "Olaparib Pill", "type": "DRUG" }, { "name": "AZD6738", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 123, "start_date": "2018-03-09", "completion_date": "2025-07-21", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03462342" }, { "nct_id": "NCT04125186", "title": "A Cross-Functional, Population-Representative, Web-Based, Epidemiologic Study to Estimate the Prevalence and Burden of Nocturia Due to Nocturnal Polyuria in the US", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Nocturnal Polyuria" ], "interventions": [ { "name": "Baseline EpiNP survey", "type": "DIAGNOSTIC_TEST" }, { "name": "Bladder diary", "type": "DIAGNOSTIC_TEST" }, { "name": "Testing of EpiNP baseline survey, bladder diary and a qualitative interview", "type": "DIAGNOSTIC_TEST" }, { "name": "No other intervention", "type": "OTHER" } ], "intervention_types": [ "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "Ferring Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 10190, "start_date": "2019-07-22", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04125186" }, { "nct_id": "NCT02784795", "title": "A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer", "Colon Cancer", "Cholangiocarcinoma", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "LY3039478", "type": "DRUG" }, { "name": "Taladegib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "LY3023414", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2016-11-04", "completion_date": "2020-02-13", "has_results": true, "last_update_posted_date": "2025-08-21", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 4, "location_summary": "Miami, Florida • Detroit, Michigan • New York, New York + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02784795" }, { "nct_id": "NCT07734077", "title": "Revumenib in Patients With Myelofibrosis", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Revumenib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "FEDRATINIB", "type": "DRUG" }, { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2026-12-01", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07734077" }, { "nct_id": "NCT05571969", "title": "Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "2X-121 600 mg", "type": "DRUG" }, { "name": "2X-121 800 mg", "type": "DRUG" }, { "name": "2X-121 1000 mg", "type": "DRUG" }, { "name": "2X-121 + 300 mg dovitinib", "type": "COMBINATION_PRODUCT" }, { "name": "2X-121 + 400 mg dovitinib", "type": "COMBINATION_PRODUCT" }, { "name": "2X-121 + 500 mg dovitinib", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "DRUG", "COMBINATION_PRODUCT" ], "sponsor": "Allarity Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2023-03-08", "completion_date": "2024-10-07", "has_results": true, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 3, "location_summary": "Huntersville, North Carolina • Cleveland, Ohio • Oklahoma City, Oklahoma", "locations": [ { "city": "Huntersville", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT05571969" }, { "nct_id": "NCT01705483", "title": "A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics of ASP9853", "Non-hematologic Malignancies" ], "interventions": [ { "name": "ASP9853", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2012-08-28", "completion_date": "2014-06-11", "has_results": false, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Detroit, Michigan • Nashville, Tennessee", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01705483" }, { "nct_id": "NCT07066722", "title": "A Study to Evaluate VH4524184 Tablet Absorption, Effects of Food, and Interactions With Other Drugs in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "VH4524184", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifabutin", "type": "DRUG" }, { "name": "Phenytoin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 126, "start_date": "2025-07-07", "completion_date": "2025-12-17", "has_results": false, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 2, "location_summary": "Lenexa, Kansas • Salt Lake City, Utah", "locations": [ { "city": "Lenexa", "state": "Kansas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT07066722" }, { "nct_id": "NCT06915753", "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Solid Tumors", "Solid Tumor, Adult", "FGFR Gene Amplification", "FGFR Gene Alterations", "Advanced Solid Tumors", "FGFR4 Gene Mutation", "FGFR4 Gene Fusions", "FGF19 Gene Amplification", "FGF19 Gene Overexpression", "Locally Advanced Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "TYRA-430", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 125, "start_date": "2025-04-24", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06915753" }, { "nct_id": "NCT01739231", "title": "Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diarrhea" ], "interventions": [ { "name": "ACE527", "type": "BIOLOGICAL" }, { "name": "dmLT", "type": "BIOLOGICAL" }, { "name": "CeraVacx placebo", "type": "BIOLOGICAL" }, { "name": "H10407 challenge strain", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "PATH", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 81, "start_date": "2012-09", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-10-09T21:02:46.035Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01739231" } ] }